Stimulating the glucose and lipid metabolism in AML is probably one of the underlying mechanisms that adjust the role of TIM-3 in AML malignant cell’s survival and higher levels of proliferation, which made TIM-3 a promising target for therapy. Here, HAVCR2 is linked to acute myeloid leukemia.